Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance
Reference number: TA161
Published: 27 October 2008
Last updated: 07 February 2018

Osteoporosis - secondary prevention including strontium ranelate: Servier response to the NICE Statement of Reasons and clarification on Servier response

Osteoporosis - secondary prevention including strontium ranelate: Servier response to the NICE Statement of Reasons
Osteoporosis - secondary prevention including strontium ranelate: appendices A and B to Servier response
Osteoporosis - secondary prevention including strontium ranelate: NICE request to Servier for clarification of their response
Osteoporosis - secondary prevention including strontium ranelate: Servier response to NICE's request for clarification
Osteoporosis - secondary prevention including strontium ranelate: appendix 1 of Servier response to clarification request

This page was last updated: 06 December 2010